58 active patients, this is very limited information. The prior quarter said 49 patients had been bought onto the trial, so presumably they have completed the trial. The trial website that the announcement refers to says that the trial is approximately 16 weeks. Too little information and subject to so much doubt. Even if the 200 actively being reviewed all were accepted into the trial, these numbers are far short of their 519 projected participants. As mentioned above, the cash burn is very high, and looks like the cash will run out prior to finalization of the trial. How is it possible to spend over $1 million on 58 (?) participants?
The information given just doesn't make sense. I had been a buy on this stock, now I just don't know as there is so much that we don't know.
AVE Price at posting:
0.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)